



Contents lists available at ScienceDirect

## AACE Clinical Case Reports

journal homepage: [www.aaclinicalcasereports.com](http://www.aaclinicalcasereports.com)

## Editorial

## Editorial for September/October Issue of AACE Clinical Case Reports

Dear Colleagues,

Welcome to another issue of *AACE Clinical Case Reports* (ACCR)! The current issue includes many interesting and educational case reports to share. We will provide a summary of some of those cases below. For more details, please access ACCR online journal available at <https://www.aaclinicalcasereports.com/>

Under the Pituitary-Gonadal-Adrenal Access in this issue, authors described the management challenges in a patient presented with symptomatic primary adrenal insufficiency due to bilateral primary adrenal lymphoma.<sup>1</sup> Another case described another endocrine-related adverse effect thought to be related to SARS-CoV-2 infection and/or vaccination. In this particular case, the authors reported a patient with hypophysitis who presented as Diabetes Insipidus after receiving SARS-CoV-2 vaccination.<sup>2</sup> An interesting visual vignette described the clinical, imaging, and biochemical manifestations of X-linked adrenoleukodystrophy in a young male patient.<sup>3</sup>

In the field of Thyroid Disease, authors reported a case of progressively increasing lytic bone lesions on the left parietal region of the skull, a biopsy of which proved the diagnosis of metastatic papillary thyroid cancer and highlighting the significance of early recognition.<sup>4</sup>

On Diabetes, Lipid, and Metabolism, authors highlighted the importance of evaluating pregnant women with gestational diabetes, as it may rarely present with diabetes ketoacidosis leading to poor fetal and maternal outcomes.<sup>5</sup> Further, an interesting 3-case-series reported on the potential complication of prolonged hypoglycemia in infants of mothers with Maturity Onset Diabetes of Youth (MODY) due to pathogenic variant in *HNF1A*, suggesting that potential link of *HNF1A* variants causing MODY may also lead to neonatal hypoglycemia.<sup>6</sup> This issue also includes an interesting visual vignette of severe abdominal lipohypertrophy due to poor insulin management.<sup>7</sup>

On Bone and Minerals, authors report an interesting case of diffuse periostitis due to the antifungal (Voriconazole) use leading to skeletal fluorosis, which can lead to diffuse bone pain.<sup>8</sup> Another interesting case reported on familial hypocalciuric hypercalcemia (FHH) with multiple family members due to calcium-sensing receptor gene (*CASR*) sequence variant [missense *CASR* in exon 3 c.392C>A (p.Ala110Asp)], currently listed under variant of unknown significance (VUS). This case suggests this *CASR* variant is pathogenic causing FHH.<sup>9</sup> Another case of hypercalcemia was also included in this issue;

the case discusses the diagnostic challenges and clinical outcome in patient with severe ectopic hyperparathyroidism and osteitis fibrosa cystica due to occult neuroendocrine tumor.<sup>10</sup>

Finally, a case included in this issue aim to raise attention to the potential side effects of hyperphosphatemic tumoral calcinosis due to Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, which blocks the effect of FGF-23 leading to hyperphosphatemia and in this case, tumoral calcinosis. The case suggests some success in treatment with lowering serum phosphate through dietary restriction and/or phosphate binders or even pemigatinib discontinuation.<sup>11</sup>

ACCR is excited to have received various submission categories other than case reports, small series, and visual vignettes, as we received submission under the new categories of video vignettes and Interpretation of Endocrine Testing. We are also accepting commentaries and letters to the Editor submissions. For detailed description of each category, please refer to "Guide to Authors" link: <https://www.elsevier.com/journals/aaace-clinical-case-reports/2376-0605/guide-for-authors>

As always, I truly appreciate all contributing authors, reviewers, editors, and staff that help improve our journal and create an educational platform to our readers to help best manage our patients.

Thank you again for your interest in ACCR. I welcome all feedback, questions, and comments from our readers. Please feel free to reach us at [publications@aaace.com](mailto:publications@aaace.com).

Warmest regards,

## References

1. Somasundaram H, Boyer P-N, Casey J, et al. Primary adrenal lymphoma as a rare cause of primary adrenal insufficiency: challenges in management and a review of the literature. *AACE Clin Case Rep.* 2022;8(5):199–203.
2. Ankireddyalli AR, Chow LS, Radulescu A, et al. A case of hypophysitis associated with SARS-CoV-2 vaccination. *AACE Clin Case Rep.* 2022;8(5):204–209.
3. Esteak T, Chowdhury S, Atiqur-Rahman M, et al. A boy with progressive cognitive impairment and darkening of skin. *AACE Clin Case Rep.* 2022;8(5):231–232.
4. Majety P, Parker JA, Hou R. Papillary thyroid cancer presenting as skull metastasis. *AACE Clin Case Rep.* 2022;8(5):233–234.
5. Villavicencio CA, Franco-Akel A, Belokovskaya R. Diabetic ketoacidosis complicating gestational diabetes mellitus. *AACE Clin Case Rep.* 2022;8(5):221–223.

6. Cromer SJ, Sella AC, Rosenberg E, et al. Report of prolonged neonatal hypoglycemia in 3 infants of mothers with HNF1A maturity-onset diabetes of the youth. *AAACE Clin Case Rep.* 2022;8(5):224–230.
7. Lee SH, Rubinova R. Severe abdominal lipohypertrophy due to poor insulin management. *AAACE Clin Case Rep.* 2022;8(5):235–236.
8. Stefan S, Altork N, Alzedaneen Y, et al. Voriconazole-induced diffuse periostitis. *AAACE Clin Case Rep.* 2022;8(5):191–193.
9. Bletsis P, Metzger R, Nelson JA, et al. A Novel missense CASR gene sequence variation resulting in familial hypocalciuric hypercalcemia. *AAACE Clin Case Rep.* 2022;8(5):194–198.
10. Yazdian A, Minuk J, Hemenway G, et al. Occult pulmonary neuroendocrine tumor causing severe hyperparathyroidism: diagnostic challenges and clinical outcomes. *AAACE Clin Case Rep.* 2022;8(5):210–216.
11. Puar A, Donegan D, Helft P, et al. Hyperphosphatemic tumoral calcinosis with pemigatinib use. *AAACE Clin Case Rep.* 2022;8(5):217–220.

Sina Jasim, MD, MPH  
Editor in Chief